Zydus Lifesciences inches up on getting USFDA`s tentative approval for Ibrutinib tablets
Zydus Lifesciences is currently trading at Rs. 973.90, up by 2.85 points or 0.29% from its previous closing of Rs. 971.05 on the BSE.
The scrip opened at Rs. 974.80 and has touched a high and low of Rs. 976.70 and Rs. 961.60 respectively. So far 5903 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 979.90 and Rs. 951.40 respectively. The current market cap of the company is Rs. 97841.16 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.26% and 6.74% respectively.
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Ibrutinib tablets 140 mg, 280 mg, and 420 mg (USRLD: Imbruvica tablets, 140 mg, 280 mg and 420 mg). Ibrutinib is a kinase inhibitor indicated for the treatment of adult patients with Chronic lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion, and Waldenstrom's macroglobulinemia (WM).
Ibrutinib tablets will be produced at Zydus Lifesciences (SEZ), Ahmedabad. Ibrutinib tablets had annual sales of $2148.9 million in the United States (IQVIA MAT May 2025). The group now has 420 approvals and has so far filed around 484 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
